Trends and insights in liver cancer from a single institution study from Main Medical Directorate of the Russian Presidential Administration over 35 years (1981-2015) Trends and insights in liver cancer from a single institution study from X over 35 years (1981-2015)

Main Article Content

Igor Olegovich Ivanikov, Prof., MD, PhD, DSc http://orcid.org/0000-0001-6691-8306 Mariia Evgenevna Zharova, MD, MSc http://orcid.org/0000-0002-8325-5927 Natalya Nikolaevna Vinogradova, MD, PhD, DSc Julia Vasilevna Grigoreva, MD, PhD http://orcid.org/0000-0001-5335-7933 Dmitry Pavlovich Ananyev, MD, PhD http://orcid.org/0000-0002-0494-4098 Oksana Valentinovna Kryuchkova, MD, PhD http://orcid.org/0000-0001-6483-2074 Natalya Vladimirovna Efremova, MD, PhD Elena Vladimirovna Myasnikova, MD, PhD Evgeniy Leonidovich Nikonov, Prof., MD, PhD, DSc http://orcid.org/0000-0002-5231-711X

Abstract

Background: This study aims to analyze liver and bile duct tumors over 35 years in the population of the Main Medical Directorate of the Russian Presidential Administration with a view to identifying epidemiological trends and their possible causes.


Objective: to assess incidence and mortality rates, examine gender-specific patterns, describe histological picture, and evaluate the effectiveness of routine screenings on patient outcomes.


Methods: Retrospective data from the cancer registry of the Main Medical Directorate of the Russian Presidential Administration for 1981-2015 were analyzed. Incidence and mortality rates were assessed with regard to gender distribution, histological confirmation, and survival rates. Standardized indicators were compared with national and international benchmarks.


Results: For a period of 35 years, 227 cases of primary liver and bile duct tumors (ICD-C22) were identified. Of these, males made up 66% (149 cases), whereas for females it was 34% (78 cases). The average age of patients was 71.6 ± 11.4 years.  The study reveals a consistent decrease in morbidity and mortality rates for both men and women within the studied population, contrasting with national trends. Study showed 20% increase in the 3-year survival rate for patients diagnosed during routine screenings compared to those presenting with symptoms (p=0.0001). Hepatocellular carcinoma was the most common type of liver cancer in the population. Surgical intervention was utilized in 16% of cases, while chemotherapy was used in 25%. Symptomatic treatment constituted a significant proportion of the treatment modalities.


Conclusion: Our study provides insights into promising epidemiological trends in liver and bile duct tumors. Factors contributing to favorable outcomes include immunization, antiviral treatments, and lower alcohol consumption. Gender-specific patterns highlight the necessity for tailored screening. This study supports the adoption of regular screening efforts to boost early detection rates and enhance patient outcomes. These findings provide significant clinical implications and pave the way for future research.

Keywords: liver neoplasms, bile duct neoplasms, incidence, survival rate, registries

Article Details

How to Cite
IVANIKOV, Igor Olegovich et al. Trends and insights in liver cancer from a single institution study from Main Medical Directorate of the Russian Presidential Administration over 35 years (1981-2015). Medical Research Archives, [S.l.], v. 12, n. 3, mar. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/5238>. Date accessed: 13 apr. 2024. doi: https://doi.org/10.18103/mra.v12i3.5238.
Section
Research Articles

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

2. Jemal A, Center MM, DeSantis C, Ward EM. Global Patterns of Cancer Incidence and Mortality Rates and Trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893-1907. doi:10.1158/1055-9965.EPI-10-0437

3. Sharma R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018. Jpn J Clin Oncol. 2020;50(12):1370-1379. doi:10.1093/jjco/hyaa130

4. Lin L, Yan L, Liu Y, Qu C, Ni J, Li H. The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017. Liver Cancer. 2020;9(5 ):563-582. doi:10.1159/000508568

5. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589-604. doi:10.1038/s41575-019-0186-y

6. Venook AP, Papandreou C, Furuse J, Ladrón de Guevara L. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. Oncologist. 2010;15(S4):5-13. doi:10.1634/theoncologist.2010-S4-05

7. Kaprin AD, Starinsky VV, Shakhzadova AO. Malignant Neoplasms in Russia in 2021 (Morbidity and Mortality). MNIOI named after. P.A. Herzen - branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia; 2022. (In Russ.)

7. Petkau VV, Bessonova EN, Breder VV, Kartashov MV, Tarkhanov AA. Cause analysis of post-mortem diagnosis of hepatocellular carcinoma. Dokazatel’naya Gastroenterol. 2023;12(1):42. (In Russ.) doi:10.17116/dokgastro20231201142

9. Petkau VV, Bessonova EN, Breder VV, Anashkina MA. Preliminary findings of hepatocellular carcinoma screening in the at-risk population. Dokazatel’naya Gastroenterol. 2023;12(4):54. (In Russ.) doi:10.17116/dokgas tro20231204154

10. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene. 2010;29(1 6):2309-2324. doi:10.1038/onc.2010.36

11. Akinyemiju T, Abera S, Ahmed M, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level. JAMA Oncol. 2017;3(12):1683. doi:10.1001/ja maoncol.2017.3055

12. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hot spot in the p53 gene in human hepatocellular carcinomas. Nature. 1991;350(6317):427-428. doi:10.1038/350427a0

13. Mancebo A, González–Diéguez ML, Cadahía V, et al. Annual Incidence of Hepatocellular Carcinoma Among Patients With Alcoholic Cirrhosis and Identification of Risk Groups. Clin Gastroenterol Hepatol. 2013;11(1):95-101. doi:10.1016/j.cgh.2012.09.007

14. Reddy KR, McLerran D, Marsh T, et al. Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study. Gastroenterology. 2023;165(4):1053-1063.e6. doi:10.1053/j.gastro.2023.06.027

15. Sohn W, Lee HW, Lee S, et al. Obesity and the risk of primary liver cancer: A systematic review and meta-analysis. Clin Mol Hepatol. 2021;27(1):157-174. doi:10.3350/cm h.2020.0176

16. Zhang H, Du X, Dong H, et al. Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database. BMC Gastroenterol. 2022;22(1):348. doi:10.1186/s12876-022-02424-5

17. Chang MH, You SL, Chen CJ, et al. Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study. JNCI J Natl Cancer Inst. 2009;101(19):1348-1355. doi:10.1093/jnci/djp288

18. Chang MH, You SL, Chen CJ, et al. Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. Gastroenterology. 2016;151(3):472-480.e1. doi:10.1053/j.gastro.2016.05.048

19. Cheemerla S, Balakrishnan M. Global Epidemiology of Chronic Liver Disease. Clin liver Dis. 2021;17(5):365-370. doi:10.1002/cld.1061

20. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. lancet Gastroenterol Hepatol. 2020;5(3):245-266. doi:10.1016/S2468-1253(19)30349-8

21. Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014;12:145. doi:10.1186 /s12916-014-0145-y

22. Su SY, Lee LT, Lee WC. Mortality trends in chronic liver disease and cirrhosis from 1981 to 2015 in Taiwan. Popul Health Metr. 2021;19(1):36. doi:10.1186/s12963-021-00269-w

23. Su S, Lee W. Mortality trends of liver diseases from 1981 to 2016 and the projection to 2035 in Taiwan: An age‐period‐cohort analysis. Liver Int. 2019;39(4):770-776. doi:10.1111/liv.14027

24. Yao Z, Dai C, Yang J, et al. Time-trends in liver cancer incidence and mortality rates in the U.S. from 1975 to 2017: a study based on the Surveillance, Epidemiology, and End Results database. J Gastrointest Oncol. 2023;14(1):312-324. doi:10.21037/jgo-23-25

25. Drepina AS, Belyakova V V., Appalup M V., Mayorova OA. Detactability of viral hepatitises in a donor contingent. Dokazatel’naya Gastroenterol. 2016;5(3):10. doi:10.17116/dokgastro20165310-17

26. Khantimirova LM, Kozlova TY, Postnova EL, Shevtsov VA, Rukavishnikov A V. Retrospective Analysis of Viral Hepatitis B Incidence in Russia from 2013 to 2017 in the Context of Preventive Vaccination. Bioprep Prev Diagnosis, Treat. 2018;18(4):225-235. doi:10.30895/2221-996X-2018-18-4-225-235

27. Mikhailova YuV, Gromov AV, Averyanova EL, Sterlikov SA. Dynamics of incidence of viral hepatitis in the population of the Russian Federation in 2015-2021. Modern problems of health care and medical statistics. 2022;(4):269-297. (In Russ.) doi:10.24412/231 2-2935-2022-4-269-297

28. Kyuregyan KK, Kichatova VS, Isaeva O V., et al. Coverage with Timely Administered Vaccination against Hepatitis B Virus and Its Influence on the Prevalence of HBV Infection in the Regions of Different Endemicity. Vaccines. 2021;9(2):82. doi:10.3390/vaccines 9020082

29. Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4(2):135-184. doi :10.1016/S24 68-1253(18)30270-X

30. Public Chamber of the Russian Federation. Alcohol Abuse in the Russian Federation: Socio-Economic Consequences and Countermeasures; 2009.

31. Nemtsov AV. Mortality in Russia in light of the in alcohol consumption. Demogr Obozr. 2015;2(4):111-135.

32. Chen LC, Wittgenstein F, McKeon E. The Upsurge of Mortality in Russia: Causes and Policy Implications. Popul Dev Rev. 1996;22(3) :517. doi:10.2307/2137719

33. Zaridze D, Brennan P, Boreham J, et al. Alcohol and cause-specific mortality in Russia: a retrospective case–control study of 48 557 adult deaths. Lancet. 2009;373(9682):2201-2214. doi:10.1016/S0140-6736(09)61034-5

34. Maev I V., Andreev DN, Kucheryavyy YA. Prevalence of non-alcoholic fat disease liver in Russian Federation: meta-analysis. Cons Medicum. 2023;25(5):313-319. doi:10.26442/ 20751753.2023.5.202155

35. Aleksandrova YD, Kolosnitsyna MG. Overweight Population in Russia: Statistical Analysis. Vopr Stat. 2018;25(10):61-77.

36. Balanova YA, Shalnova SA, Deev AD, et al. Obesity in Russian population — prevalence and association with the non-communicable diseases risk factors. Russ J Cardiol. 2018;(6):1 23-130. doi:10.15829/1560-4071-2018-6-123-130

37. Kontsevaya A, Shalnova S, Deev A, et al. Overweight and Obesity in the Russian Population: Prevalence in Adults and Association with Socioeconomic Parameters and Cardiovascular Risk Factors. Obes Facts. 2019;12(1):103-114. doi:10.1159/000493885

38. Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol. 2017;8(6):429-436. doi:10.5306/wjco.v8.i6.429

39. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37 Suppl 1:81-84. doi:10.1111/liv.13299

40. Sheiman I, Shishkin S, Shevsky V. The evolving Semashko model of primary health care: the case of the Russian Federation. Risk Manag Healthc Policy. 2018;Volume 11:209-220. doi:10.2147/RMHP.S168399

41. Shishkin S, Sheiman I, Vlassov V, Potapchik E, Sazhina S. Structural changes in the Russian health care system: do they match European trends? Health Econ Rev. 2022;12(1):29. doi:10.1186/s13561-022-00373-z

42. Tagaeva T, Kazantseva L. Social impacts of health care reforms in Russia. Rudoy D, Olshevskaya A, Kankhva V, eds. E3S Web Conf. 2020;210:17011. doi:10.1051/e3sconf/ 202021017011

43. Yao Z, Dai C, Yang J, et al. Time-trends in liver cancer incidence and mortality rates in the U.S. from 1975 to 2017: a study based on the Surveillance, Epidemiology, and End Results database. J Gastrointest Oncol. 2023;14(1):312-324. doi:10.21037/jgo-23-25

44. Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer. 2016;139(7):1534-1545. doi:10.1002/ijc.30211

45. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7). doi:10.1007/s00432-004-0552-0

46. Singal AG, Pillai A, Tiro J. Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis. Klenerman P, ed. PLoS Med. 2014;11(4):e100 1624. doi:10.1371/journal.pmed.1001624